NAUT · Nautilus Biotechnology, Inc.
$2.19
+0.37 (+20.32%)
At close · Oct 9
Return incl. dividend (before tax)
Market Cap
$231.60M
Shares
127.26M
Volume · Oct 9
4.64M
Avg daily vol (3M)
2.65M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.82
Open$2.00
Day$1.75–2.01
52W close$0.85–3.95
Avg vol 30d4.8M
Short int4.1M · 3.2% float · 3.2d
Short vol54%
Last earningsJul 28, 2026
DataAug 2020–Oct 2026
Filing10-Q · Jul 28
Up next
Next earnings call
Oct 26, 2026
Est · unconfirmed
· in 2 wks
filed Jul 28, 2026
call held Jul 28, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$56.52M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-22.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$13.17M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.7%
Year over year · more shares
Price change (1Y)
+101.8%
Trailing year
Short interest
3.2%
Latest settlement · 3.2 days to cover
AI Brief
Q2 FY26 earnings call · Jul 28, 2026
Q2 FY26
TL;DR. Nautilus is shifting the majority of its R&D resources from the broad-scale proteome application to its Proteoform application, delaying broad-scale general availability beyond 2027, while recording its first revenue and lowering full-year operating expense guidance.
Bullish
- + Reported first revenue of $0.2M in Q2 2026 from Michael J. Fox grant and first early access customer.
- + Operating expenses fell to $15.9M, down ~7% year-over-year, with R&D down ~8% and SG&A down ~6%.
- + Voyager platform pre-orders expected early 2027 with shipments beginning mid-2027, targeting ~$1M instrument price.
Bearish
- − Broad-scale consumable kit will not support 2027 general availability at target specifications; broad-scale timeline withdrawn.
- − Net loss of $14.5M, though modestly improved from $15.0M prior-year, with quarterly cash use of ~$14.2M.
- − Broad-scale team cut by roughly half and its development pace will slow as resources shift to proteoforms.
- − Anticipates raising additional capital between now and mid-2027, signaling need for funding despite runway into Q1 2028.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−12%
below
Price vs 50-day avg
+71%
above
RSI (14)
68
neutral
MACD trend
Positive
52-week position
31%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+84%
trailing
6-month return
−40%
trailing
YTD return
−7%
this year
Relative strength
−49%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 93 funds reported for Sep 30 · net +3.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.21% of float · ▲ +7.0% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
93 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
EPS growth
+16%
Y/Y
Free cash flow
$-52.0M
Quant / Vol
risk profile
Volatility
119%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
12.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
Revenue
· full year
$500,000
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−12%
Bearish
Price vs 50-day avg
+71%
Bullish
RSI (14)
68
Neutral
MACD trend
Positive
Bullish
52-week position
31%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
1 of 93 funds reported for Sep 30 · net +3.5K sh shares · +1 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.21% of float · ▲ +7.0% MoM · 3.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
93 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 31%
Range high $4
vs 200-day avg -12%
vs 50-day avg +71%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NAUT
this stock
Nautilus Biotechnology, Inc.
|
$231.60M | -6.7% | — | — | 3.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$127.55B | +11.0% | +46.2% | 29.3 | 1.9% |
|
MRNA
Moderna, Inc.
|
$78.65B | +568.0% | +4.3% | — | 8.2% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.14B | -4.2% | +20.8% | 18.3 | 2.5% |
|
CSLLY
Csl Ltd
|
$60.24B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NAUT | +15.9% | +83.8% | -39.9% | +28.2% | -6.7% |
| SPY | +1.3% | +2.1% | +9.0% | +1.5% | +13.5% |
| vs SPY | +14.6% | +81.7% | -48.9% | +26.7% | -20.2% |